Latest Camber Capital Management LP Stock Portfolio
Camber Capital Management LP Performance:
2025 Q2: -7.71%YTD: -9.25%2024: 3.62%
Performance for 2025 Q2 is -7.71%, and YTD is -9.25%, and 2024 is 3.62%.
About Camber Capital Management LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Camber Capital Management LP reported an equity portfolio of $1.1 Billions as of 30 Jun, 2025.
The top stock holdings of Camber Capital Management LP are ZBH, BAX, HUM. The fund has invested 8.6% of it's portfolio in ZIMMER BIOMET HOLDINGS INC and 8.1% of portfolio in BAXTER INTL INC.
The fund managers got completely rid off PTC THERAPEUTICS INC (PTCT), THE CIGNA GROUP (CI) and QIAGEN NV stocks. They significantly reduced their stock positions in ANAPTYSBIO INC (ANAB), CONCENTRA GROUP HOLDINGS PAR and EVOLENT HEALTH INC (EVH). Camber Capital Management LP opened new stock positions in ICON PLC, MERCK & CO INC (MRK) and UNITEDHEALTH GROUP INC (UNH). The fund showed a lot of confidence in some stocks as they added substantially to BIOMARIN PHARMACEUTICAL INC (BMRN).
The top stock holdings of Camber Capital Management LP are ZBH, BAX, HUM. The fund has invested 8.6% of it's portfolio in ZIMMER BIOMET HOLDINGS INC and 8.1% of portfolio in BAXTER INTL INC.
The fund managers got completely rid off PTC THERAPEUTICS INC (PTCT), THE CIGNA GROUP (CI) and QIAGEN NV stocks. They significantly reduced their stock positions in ANAPTYSBIO INC (ANAB), CONCENTRA GROUP HOLDINGS PAR and EVOLENT HEALTH INC (EVH). Camber Capital Management LP opened new stock positions in ICON PLC, MERCK & CO INC (MRK) and UNITEDHEALTH GROUP INC (UNH). The fund showed a lot of confidence in some stocks as they added substantially to BIOMARIN PHARMACEUTICAL INC (BMRN).
Camber Capital Management LP Annual Return Estimates Vs S&P 500
Our best estimate is that Camber Capital Management LP made a return of -7.71% in the last quarter. In trailing 12 months, it's portfolio return was -10.39%.
New Buys
| Ticker | $ Bought |
|---|---|
| icon plc | 43,635,000 |
| merck & co inc | 39,580,000 |
| unitedhealth group inc | 31,197,000 |
| apellis pharmaceuticals inc | 14,713,500 |
New stocks bought by Camber Capital Management LP
Additions
| Ticker | % Inc. |
|---|---|
| biomarin pharmaceutical inc | 20.00 |
Additions to existing portfolio by Camber Capital Management LP
Reductions
| Ticker | % Reduced |
|---|---|
| anaptysbio inc | -83.33 |
| concentra group holdings par | -75.00 |
| evolent health inc | -71.67 |
| denali therapeutics inc | -68.00 |
| brookdale sr living inc | -65.6 |
| viatris inc | -63.33 |
| humana inc | -58.62 |
| zimmer biomet holdings inc | -55.56 |
Camber Capital Management LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| ptc therapeutics inc | -76,440,000 |
| qiagen nv | -56,210,000 |
| 10x genomics inc | -8,730,000 |
| sarepta therapeutics inc | -51,056,000 |
| ionis pharmaceuticals inc | -21,873,200 |
| moonlake immunotherapeutics | -17,229,900 |
| structure therapeutics inc | -5,193,000 |
| the cigna group | -65,800,000 |
Camber Capital Management LP got rid off the above stocks
Sector Distribution
Camber Capital Management LP has about 86.8% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 86.8 |
| Others | 13.2 |
Market Cap. Distribution
Camber Capital Management LP has about 68% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| LARGE-CAP | 58.1 |
| UNALLOCATED | 13.2 |
| MID-CAP | 12.2 |
| MEGA-CAP | 9.9 |
| SMALL-CAP | 5.6 |
Stocks belong to which Index?
About 73.6% of the stocks held by Camber Capital Management LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| S&P 500 | 63.4 |
| Others | 26.5 |
| RUSSELL 2000 | 10.2 |
Camber Capital Management LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Camber Capital Management LP
Camber Capital Management LP has 23 stocks in it's portfolio. About 53.2% of the portfolio is in top 10 stocks. ZBH proved to be the most loss making stock for the portfolio. EVH was the most profitable stock for Camber Capital Management LP last quarter.
Last Reported on: 14 Aug, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ANAB | anaptysbio inc | 0.26 | 125,000 | 2,775,000 | reduced | -83.33 | ||
| APLS | apellis pharmaceuticals inc | 1.38 | 850,000 | 14,713,500 | new | |||
| BAX | baxter intl inc | 8.10 | 2,850,000 | 86,298,000 | reduced | -50.43 | ||
| BKD | brookdale sr living inc | 1.41 | 2,150,000 | 14,964,000 | reduced | -65.6 | ||
| BMRN | biomarin pharmaceutical inc | 3.10 | 600,000 | 32,982,000 | added | 20.00 | ||
| CI | the cigna group | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CVS | cvs health corp | 6.80 | 1,050,000 | 72,429,000 | reduced | -53.33 | ||
| DNLI | denali therapeutics inc | 0.52 | 400,000 | 5,596,000 | reduced | -68.00 | ||
| EVH | evolent health inc | 0.90 | 850,000 | 9,571,000 | reduced | -71.67 | ||
| GMED | globus med inc | 4.43 | 800,000 | 47,216,000 | reduced | -36.00 | ||
| HUM | humana inc | 6.88 | 300,000 | 73,344,000 | reduced | -58.62 | ||
| INGN | inogen inc | 0.64 | 975,000 | 6,854,250 | unchanged | 0.00 | ||
| IONS | ionis pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| MLTX | moonlake immunotherapeutics | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| MRK | merck & co inc | 3.72 | 500,000 | 39,580,000 | new | |||
| MYGN | myriad genetics inc | 1.00 | 2,000,000 | 10,620,000 | reduced | -14.89 | ||
| OSUR | orasure technologies inc | 0.25 | 900,000 | 2,700,000 | unchanged | 0.00 | ||
| PFE | pfizer inc | 3.41 | 1,500,000 | 36,360,000 | reduced | -40.00 | ||
| PTCT | ptc therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| SRPT | sarepta therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||